Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- Novartis
- Roche
- Boehringer Ingelheim
- Bayer
- Cancer Research UK (C2930/A11428, C480/A15578, C5759/A27412, CRUK/09/029)
- British Microcirculation & Vascular Biology Society
- Amgen
- Servier
- AstraZeneca
- Astex Pharmaceuticals
- Manchester Biomedical Research Centre
This publication has 17 references indexed in Scilit:
- Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR ExpressionClinical Cancer Research, 2017
- Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapyOncotarget, 2017
- Antiangiogenic therapy in oncology: current status and future directionsThe Lancet, 2016
- Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumabBritish Journal of Cancer, 2016
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialThe Lancet Oncology, 2015
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialThe Lancet Oncology, 2013
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid CellsCancer Cell, 2011
- ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial useJournal of Immunological Methods, 2009
- Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast CancerJournal of Clinical Oncology, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)European Journal of Cancer, 2005